Sarah E. Canetta
My laboratory investigates the neural circuitry of cognitive and affective behaviors, with a particular focus on how experiences encountered during ‘sensitive periods’ shape the development of this circuitry and impact behavior all the way into adulthood. To do this, we use a multi-disciplinary investigative strategy in mice including in vivo recordings of activity during behavior, opto- and pharmacogenetic manipulations of circuit activity and measurements of synaptic function and anatomy using in vitro slice electrophysiology and histology. Through this approach we hope to gain insight into the typical developmental trajectory of brain circuits supporting cognitive and affective behaviors, as well as the etiology of cognitive and affective symptoms associated with disorders like schizophrenia, anxiety, depression and substance abuse.
The concept of sensitive periods is essential to our understanding of how the environment shapes brain development. However, the study of sensitive periods in cortical development has predominantly focused on sensory regions, where sensory experiences refine cortical development via alterations in activity. We have recently identified a prefrontal adolescent sensitive period in which transiently decreasing the activity of a population of interneurons that express the molecular marker, parvalbumin (PV), leads to long-lasting effects on the integration of these cells in prefrontal circuitry, prefrontal network function and behavioral flexibility measured in an extradimensional set-shifting task (Canetta et al, bioRxiv, 2021). This finding demonstrates the necessity of neuronal activity for prefrontal cortical circuit development and addresses the long-standing question in the field regarding whether there are activity-dependent sensitive time windows governing the maturation of this structure, similar to what has been seen in the sensory cortex. This finding also serves as the basis for several ongoing interests of the lab: 1) What are the mechanisms that determine the timing of this sensitive period for heightened plasticity for activity-dependent remodeling? and 2) What are environmental experiences or factors that modulate endogenous PV interneuron activity during development?
While studying cognitive flexibility in the adult animal, we identified a new mechanism by which the prefrontal cortex regulates extradimensional set-shifting behavior. Specifically, we identified a task-induced increase in gamma frequency power when mice are preparing to make a choice during set-shifting. This induction in gamma oscillatory power was only observed in correct, but not incorrect, trials, and predicted whether mice subsequently made correct or incorrect choices. Another project in the laboratory is focused on understanding how PV interneurons utilize gamma oscillations to organize the activity of task-relevant neuronal ensembles to support set shifting behavior.
A final project in the laboratory is examining how brief, early postnatal exposure to the selective serotonin reuptake inhibitor, fluoxetine (FLX), results in increases in affective behavior in adulthood that are resistant to subsequent chronic treatment with FLX, but normalized by treatment with the atypical antidepressant, tianeptine (Pekaraskaya & Holt et al, bioRxiv, 2020). Mouse brain development occurring during this postnatal exposure window is comparable to brain development occurring in the third trimester of a human pregnancy, making these developmentally FLX-exposed mice a model of human exposure to SSRIs in utero. Focusing on reward processing, we are investigating the neural circuit underpinnings of this SSRI-resistance as well as how tianeptine remains effective in this early exposure model. The goal of these studies is to define the neurophysiological and behavioral mechanisms underlying different antidepressant pharmacotherapies, as well as improve our understanding of why they can be ineffective in certain individuals.
7/2013-6/2015, Columbia University, New York, NY, Sackler Fellow in Developmental Psychobiology (laboratory of Dr. Christoph Kellendonk)
7/2010-7/2013, Columbia University, New York, NY, T32 Post-doctoral Fellow in Child Psychiatry (laboratory of Dr. Christoph Kellendonk)
9/2004-10/2010, Columbia University, New York, NY, PhD, Neurobiology and Behavior
9/2004-6/2007, Columbia University, New York, NY, MPhil, Neurobiology and Behavior
9/2004-6/2005, Columbia University, New York, NY, MS, Neurobiology and Behavior
9/1999-5/2003, Yale University, New Haven, CT, BA, Psychology (Behavioral Neuroscience), Cum Laude
2021 C3N Seminar Speaker, Columbia University Department of Psychiatry
2020 Panel speaker, American College of Neuropsychopharmacology
2020 Biological Sciences Seminar Speaker, Fordham University
2020 Hot topics speaker, Columbia University Department of Psychiatry Grand Rounds
2019 American College of Neuropsychopharmacology Travel Award
2018 Symposium speaker, International Society for Developmental Psychobiology (selected as the Sackler Award Symposium)
2018 Brain and Behavior Research Foundation Young Investigator Award
2017 Invited short talk, Cold Spring Harbor Wiring the Brain Conference
2015 International Congress of Schizophrenia Research Young Investigator Travel Award
2015 Invited short talk, International Congress of Schizophrenia Research
2014 Brain and Behavior Research Foundation Young Investigator Award
2013 Sackler Fellowship in Developmental Psychobiology
2010 T32 Fellowship in Child Psychiatry, appointed co-Chief Fellow (2011-2012)
2009 Travel Scholarship, Keystone Conference, “Neurobiology of Pain and Analgesia”
2009 Invited short talk, Keystone Conference, “Neurobiology of Pain and Analgesia”
2008-2009 NIH T32 Translation Research Training Scholarship, Columbia University